Company Monitoring Page for Eisai

latest headlines for company on cafepharma

What Would a Donanemab Approval Mean for Leqembi?
BioSpace
Mon, 06/24/24 - 10:47 am
Tags:
Eli Lilly, donanemab, Biogen, Eisai, Leqembi, FDA, Alzheimer's disease
FDA accepts Eisai's subcutaneous Leqembi filing, sets January 25 decision date
Fierce Pharma
Mon, 06/10/24 - 11:19 am
Tags:
Eisai, Biogen, Leqembi, FDA, Alzheimer's disease
ASCO: With Opdivo-Yervoy combo, Bristol Myers calls Roche and AstraZeneca's bets in first-line liver cancer
Fierce Pharma
Tue, 06/4/24 - 11:52 am
Tags:
ASCO 2024, Bristol Myers Squibb, Opdivo, Yervoy, liver cancer, Merck, Eisai, Bayer, Lenvima, Nexavar
Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
Reuters
Tue, 05/14/24 - 11:03 pm
Tags:
Eisai, Biogen, Leqembi, FDA, Alzheimer's disease
Alzheimer's drug adoption in US slowed by doctors' skepticism
Reuters
Tue, 04/23/24 - 09:47 pm
Tags:
Eisai, Biogen, Leqembi, physicians, Alzheimer's disease
Eisai hunts for next Alzheimer’s drug with new research pact
BioPharma Dive
Mon, 04/22/24 - 05:49 pm
Tags:
Eisai, R&D, Alzheimer's disease, BioArctic
Lilly Alzheimer's med glides out of Leqembi's slipstream with FDA adcomm request
Fierce Biotech
Wed, 04/17/24 - 09:58 pm
Tags:
Eli Lilly, donanemab, Alzheimer's disease, Leqembi, Biogen, Eisai, FDA
Biogen and Eisai Fall Behind on Leqembi’s Subcutaneous BLA for Alzheimer’s
BioSpace
Mon, 04/1/24 - 12:14 pm
Tags:
Biogen, Eisai, Alzheimer's disease, Leqembi
Eisai and Biogen facing delay to Leqembi in Europe
Pharmaphorum
Mon, 03/25/24 - 11:22 am
Tags:
Eisai, Biogen, Leqembi, Europe, Alzheimer's disease
Eisai backs Leqembi’s Japan rollout with insurance policy
Pharmaphorum
Thu, 03/21/24 - 11:19 am
Tags:
Eisai, Lifenet, insurance, Leqembi, dementia
FDA guidelines consider amyloid reduction 'reasonably likely' to predict Alzheimer's benefit
Fierce Biotech
Tue, 03/12/24 - 11:34 am
Tags:
Biogen, Eisai, Aduhelm, FDA, Alzheimer's disease, amyloid, Eli Lilly, donanemab
Tau, anti-inflammation and orals form Biogen's future Alzheimer's pipeline
Fierce Biotech
Thu, 03/7/24 - 11:38 am
Tags:
Biogen, Alzheimer's disease, anti-tau antibodies, anti-inflammatory, Eisai, Leqembi
Japan's Eisai says US introduction of Alzheimer's drug Leqembi slower than expected
Reuters
Thu, 03/7/24 - 11:07 am
Tags:
Eisai, Leqembi, drug launches, Alzheimer's disease
Eisai, Biogen likely to miss early launch goal for Alzheimer's drug Leqembi
Fierce Pharma
Wed, 02/7/24 - 11:33 am
Tags:
Eisai, Biogen, FDA, Medicare, Leqembi, Alzheimer's disease
EU regulators to consult advisers in review of Eisai Alzheimer’s drug
BioPharma Dive
Thu, 01/11/24 - 08:40 pm
Tags:
Eisai, Leqembi, Europe, Alzheimer's disease
Eisai files biliary tract cancer drug tasurgratinib in Japan
Pharmaphorum
Mon, 12/18/23 - 10:14 am
Tags:
Eisai, Japan, tasurgratinib, biliary tract cancer
Merck-Eisai's endometrial cancer therapy combo fails first-line treatment trial
Reuters
Fri, 12/8/23 - 09:59 am
Tags:
Merck, Eisai, 4523.T, clinical trials, endometrial cancer, Keytruda, Lenvima
Eisai expects Alzheimer's drug to rake in revenue of $66.5 million by March
Reuters
Tue, 11/7/23 - 09:57 am
Tags:
Eisai, Leqembi, Alzheimer's disease
Eisai says new data could support more convenient form of Alzheimer’s drug Leqembi
BioPharma Dive
Wed, 10/25/23 - 10:42 pm
Tags:
Eisai, Biogen, Leqembi, Alzheimer's disease
As 'harvest time' arrives for Alzheimer's, neuroscientist reflects on next steps for drug development
Fierce Biotech
Mon, 10/16/23 - 10:12 am
Tags:
Alzheimer's disease, Biogen, Eisai, Eli Lilly, Leqembi, donanemab

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.